Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Classical hematology 1CNS 1

Conditions

Thrombocytopenia 1Lymphoma 1Intraocular Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 3Etoposide 2Cytarabine 2Carboplatin 2Busulfan 2sodium thiosulfate 1pegfilgrastim 1merphos 1fludarabine phosphate 1etoposide phosphate 1Whole-Body Irradiation 1Vorinostat 1Valganciclovir 1Thiotepa 1Therapeutics 1Tacrolimus 1Rituximab 1Polymerase Chain Reaction 1Methotrexate 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Ganciclovir 1Foscarnet 1Fluorescent Antibody Technique 1Flow Cytometry 1Filgrastim 1Enzyme-Linked Immunosorbent Assay 1Drug Therapy 1Deferasirox 1Dapsone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intraocular Lymphoma × etoposide phosphate × Classical hematology × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡